Literature DB >> 2763305

Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects.

Y Singh1, L Ulrich, D Katz, P Bowen, G Krishna.   

Abstract

By employing rat cardiac myocytes in culture and mouse L-1210 leukemia cells, we have compared different anthracycline analogs with respect to their ability to kill cardiac myocytes and tumor cells. Anthracyclines induced a decrease in cellular ATP and glutathione from both cardiac myocytes and L-1210 cells in a time- and concentration-dependent fashion. Moreover, the decrease in ATP in cardiac myocytes was followed by release of the cytoplasmic enzyme lactic acid dehydrogenase and of adenine nucleotides after anthracycline treatment. At very low concentrations of anthracyclines, at which ATP and glutathione were not affected, the drugs induced complete cessation of the growth of L-1210 cells. Some structural alterations in the anthracycline molecule resulted in parallel changes in antitumor activity and in cardiotoxicity. But other structural alterations resulted in dissimilar changes in antitumor activity and cardiotoxicity. Although the results indicate that the structural requirements for inducing cardiotoxicity and antitumor activity may be different, they also indicate that the mechanisms by which anthracycline causes cell death in tumor cells and cardiac myocytes may be the same.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2763305     DOI: 10.1016/0041-008x(89)90087-2

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  An Emerging Pathway of Doxorubicin Cardiotoxicity Mediated through CYP2J2.

Authors:  William R Arnold; Aditi Das
Journal:  Biochemistry       Date:  2018-04-09       Impact factor: 3.162

2.  Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.

Authors:  William R Arnold; Javier L Baylon; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2017-12-12       Impact factor: 3.162

3.  Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.

Authors:  C Agen; N Bernardini; R Danesi; P Della Torre; M Costa; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Anthracycline derivatives inhibit cardiac CYP2J2.

Authors:  Justin S Kim; Andres S Arango; Swapnil Shah; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  J Inorg Biochem       Date:  2022-01-13       Impact factor: 4.155

5.  A computational study of Anthracyclines interacting with lipid bilayers: Correlation of membrane insertion rates, orientation effects and localisation with cytotoxicity.

Authors:  D Toroz; I R Gould
Journal:  Sci Rep       Date:  2019-02-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.